Argent BioPharma Limited (ASX:RGT)
Australia · Delayed Price · Currency is AUD 0.0610
+0.0050 (8.93%)
Feb 11, 2026, 11:21 AM AEST
Argent BioPharma Revenue
In the fiscal year ending June 30, 2025, Argent BioPharma had annual revenue of 180.57K AUD, down -79.74%. Argent BioPharma had revenue of 176.28K in the half year ending June 30, 2025, a decrease of -75.68%.
Revenue
180.57K
Revenue Growth
-79.74%
P/S Ratio
26.96
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 180.57K | -710.52K | -79.74% |
| Jun 30, 2024 | 891.08K | -2.50M | -73.70% |
| Jun 30, 2023 | 3.39M | -1.34M | -28.41% |
| Jun 30, 2022 | 4.73M | 1.74M | 57.94% |
| Jun 30, 2021 | 3.00M | 916.88K | 44.10% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vitura Health | 124.04M |
| Little Green Pharma | 38.49M |
| IDT Australia | 19.77M |
| ECS Botanics Holdings | 19.36M |
| Elixinol Wellness | 15.85M |
| Peak Processing | 15.49M |
| Cann Group | 13.25M |
| Epsilon Healthcare | 6.13M |